Media Room

For Immediate Release

Truven Health Analytics and Florida Health Care Coalition Study Finds Value-Based Insurance Programs Improve Diabetes Outcomes

Study Links Presence of Value-Based Insurance and Disease Management Programs to Better Results, Controlled Costs

Ann Arbor, MI, Jun. 19, 2013 — Diabetes treatment is more effective when paired with both value-based benefit design and disease management programs, according to a joint study from Truven Health Analytics™ and the Florida Health Care Coalition.
The paper, Value-Based Design and Prescription Drug Utilization Patterns Among Diabetes Patients, which appears in the MayJune issue of The American Journal of Pharmacy Benefits, examined the three year effect of value-based design and disease management programs on diabetes patients.   Value-based insurance design is a medical benefit plan design that aligns patient cost-sharing with the clinical value of health services, providing lower out-of-pocket costs for proven, high value services and higher out-of-pocket prices for lower value services.

The study evaluated medication adherence and usage based on possession ratios and usage rates and found that patients enrolled in value-based benefit design in conjunction with a disease management program showed higher adherence to both brand and generic oral medications and a higher uptake of insulin over the course of the three year study period.

“These results suggest that by reducing patient cost-sharing for antidiabetic medications, employers are able to increase utilization rates among employees with chronic disease, ” said Teresa Gibson, PhD, vice president, health outcomes, at Truven Health Analytics and lead author of the study. “Though most studies of this type have examined the effects of medication use in aggregate, the design of the value-based program we examined allowed us to determine whether effects were consistent across brand and generic medications.”

The study analyzed 1876 diabetes patients that were enrolled in a value-based program and a disease management program. It compared them to two identically sized groups:  diabetes patients with only a disease management program, and those with neither a value-based or disease management program.

“Value-based benefit designs were founded on the simple premise that by reducing patient out-of-pocket costs for treatments that are known to be effective, it becomes less burdensome for patients to manage their health, ” said John “Jack” Mahoney, MD, Florida Health Care Coalition chief medical officer.  “This research moves that theory forward, allowing the hundreds of companies currently implementing value-based designs to tailor their programs to produce the highest-quality health care at the lowest cost.”

The Truven Health Advantage Suite and the Truven Health MarketScan® Research Databases, which contain de-identified healthcare claims data reflecting the real-world medical care of over 180 million unique patients across the U.S. since 1995, were used to conduct the analysis.  Funding for the research was provided by Merck.

To read the complete study in The American Journal of Pharmacy Benefits, click here.

About the Florida Health Care Coalition

The Florida Health Care Coalition is a non-profit group of employers from Florida representing nearly two million covered lives.  The mission of the coalition is to educate employers, consumers, health plans and providers and bring them together as one to help improve the quality of health care not only in Florida but nationwide.  Staffed by a  team of experts in benefit design and population health and wellness, the Florida Health Care Coalition also counts among its board members representatives from Walt Disney Parks & Resorts, Universal Orlando, the City of Orlando, Miami Dade Public Schools, Lockheed Martin, Orange County Public Schools and many other large employers.  For more information on the Florida Health Care Coalition, please visit us on the web: www.flhcc.org.

About Truven Health Analytics, part of the IBM Watson Health Business

Truven Health Analytics®, part of the IBM Watson Health™ business, provides market-leading performance improvement solutions built on data integrity, advanced analytics and domain expertise. For more than 40 years, our insights and solutions have been providing hospitals and clinicians, employers and health plans, state and federal government agencies, life sciences companies and policymakers, the facts they need to make confident decisions that directly affect the health and well-being of people and organizations in the US and around the world. The company was acquired by IBM in 2016 to help form a new business, Watson Health. Watson Health aspires to improve lives and give hope by delivering innovation to address the world’s most pressing health challenges through data and cognitive insights.

Truven Health Analytics owns some of the most trusted brands in healthcare, such as MarketScan®, 100 Top Hospitals®, Advantage Suite®, Micromedex®, Simpler® and ActionOI®. Truven Health has its principal offices in Ann Arbor, MI, Chicago, IL, and Denver, CO.


Brian Erni
For Truven Health Analytics
J. Roderick, Inc. Public Relations